Comparison of drug-induced liver injury risk between propylthiouracil and methimazole: A quantitative systems toxicology approach.

DILIsym Drug induced livery injury Methimazole Physiologically based pharmacokinetic model Propylthiouracil Quantitative systems toxicology

Journal

Toxicology and applied pharmacology
ISSN: 1096-0333
Titre abrégé: Toxicol Appl Pharmacol
Pays: United States
ID NLM: 0416575

Informations de publication

Date de publication:
07 Aug 2024
Historique:
received: 04 06 2024
revised: 23 07 2024
accepted: 06 08 2024
medline: 10 8 2024
pubmed: 10 8 2024
entrez: 9 8 2024
Statut: aheadofprint

Résumé

Propylthiouracil (PTU) and methimazole (MMI), two classical antithyroid agents possess risk of drug-induced liver injury (DILI) with unknown mechanism of action. This study aimed to examine and compare their hepatic toxicity using a quantitative system toxicology approach. The impact of PTU and MMI on hepatocyte survival, oxidative stress, mitochondria function and bile acid transporters were assessed in vitro. The physiologically based pharmacokinetic (PBPK) models of PTU and MMI were constructed while their risk of DILI was calculated by DILIsym, a quantitative systems toxicology (QST) model by integrating the results from in vitro toxicological studies and PBPK models. The simulated DILI (ALT >2 × ULN) incidence for PTU (300 mg/d) was 21.2%, which was within the range observed in clinical practice. Moreover, a threshold dose of 200 mg/d was predicted with oxidative stress proposed as an important toxic mechanism. However, DILIsym predicted a 0% incidence of hepatoxicity caused by MMI (30 mg/d), suggesting that the toxicity of MMI was not mediated through mechanism incorporated into DILIsym. In conclusion, DILIsym appears to be a practical tool to unveil hepatoxicity mechanism and predict clinical risk of DILI.

Identifiants

pubmed: 39122118
pii: S0041-008X(24)00262-X
doi: 10.1016/j.taap.2024.117064
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

117064

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that there are no financial relationships or conflicts of interest that could be perceived as influencing the content. This includes, but is not limited to, employment, consultancies, honoraria, stock ownership, or any other form of financial involvement with companies or organizations mentioned.

Auteurs

Qingfeng He (Q)

Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai 201203, China.

Min Li (M)

Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai 201203, China.

Peiying Ji (P)

Department of Pharmacy, Kong Jiang Hospital of Yangpu District, Shanghai 200093, PR China.

Aole Zheng (A)

Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai 201203, China.

Li Yao (L)

Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai 201203, China.

Xiao Zhu (X)

Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai 201203, China.

Jae-Gook Shin (JG)

Department of Pharmacology and Pharmacogenomics Research Center, Inje University College of Medicine, Busan 47392, Republic of Korea.

Volker M Lauschke (VM)

Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

Bing Han (B)

Department of Pharmacy, Minhang Hospital, Fudan University, Shanghai, China. Electronic address: hbshcn@fudan.edu.cn.

Xiaoqiang Xiang (X)

Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai 201203, China. Electronic address: xiangxq@fudan.edu.cn.

Classifications MeSH